Methods and materials for modulation of the immunosuppresive activity and toxicity of monoclonal antibodies
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Dec 10, 2002
Issued Date -
N/A
app pub date -
Oct 9, 1998
filing date -
Jun 1, 1994
priority date (Note) -
In Force
status (Latency Note)
Importance
Abstract
The binding specificity of the murine OKT3 has been transferred into a human antibody framework in order to reduce its immunogenicity. These 'humanized' anti-CD3 monoclonal antibodies retain, in vitro, all the properties of native anti-CD3 antibodies, including T cell activation which has been correlated, in vivo, with the severe side-effects observed in transplant recipients after the first administration of the mAb.
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully